Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2007;50:1114-1119
Published online before print November 5, 2007, doi: 10.1161/HYPERTENSIONAHA.107.097634
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
50/6/1114    most recent
HYPERTENSIONAHA.107.097634v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Conen, D.
Right arrow Articles by Zee, R. Y.L.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Conen, D.
Right arrow Articles by Zee, R. Y.L.
Right arrowPubmed/NCBI databases
*Gene*GEO Profiles
*HomoloGene*SNP
*UniGene
Related Collections
Right arrow Clinical Studies
Right arrow Epidemiology
Right arrow Other etiology

(Hypertension. 2007;50:1114.)
© 2007 American Heart Association, Inc.


Original Articles

Natriuretic Peptide Precursor A Gene Polymorphisms and Risk of Blood Pressure Progression and Incident Hypertension

David Conen; Robert J. Glynn; Julie E. Buring; Paul M Ridker; Robert Y.L. Zee

From the Division of Preventive Medicine, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass.

Correspondence to David Conen, Division of Preventive Medicine, Brigham and Women’s Hospital, 900 Commonwealth Ave East, Boston, MA 02215. E-mail conend{at}uhbs.ch

We tested the hypothesis that natriuretic peptide precursor A gene polymorphisms are significantly associated with blood pressure progression and incident hypertension among healthy, middle-aged women. We performed a prospective cohort study among 18 437 white women participating in the Women’s Health Study who were free of hypertension at baseline. Two previously characterized single nucleotide polymorphisms within the natriuretic peptide precursor A gene (rs5063 G>A and rs5065 T>C) were genotyped. Blood pressure progression at 48 months and incident hypertension during the entire follow-up according to the different genotypes and inferred haplotypes were assessed by logistic regression and Cox proportional hazards models, respectively. At 48 months, 47.4% of women had blood pressure progression. The odds ratio (95% CIs) for blood pressure progression associated with the rs5063 variant was 0.85 (0.76 to 0.94; P=0.002). For the rs5065 variant, the corresponding odds ratio was 0.94 (0.88 to 1.00; P=0.050). During 9.8 years of follow-up, 29.6% of women developed incident hypertension. Hazard ratios (95% CIs) for incident hypertension were 0.88 (0.80 to 0.96; P=0.005) for the rs5063 variant and 0.95 (0.90 to 1.00; P=0.068) for the rs5065 variant. The odds ratios (95% CIs) of blood pressure progression for the G-T, G-C, and A-T haplotypes were 1.0 (referent), 0.91 (0.85 to 0.98; P=0.007), and 0.80 (0.71 to 0.89; P<0.001), respectively. For incident hypertension, the corresponding hazard ratios were 1.0 (referent), 0.95 (0.90 to 1.01; P=0.095), and 0.90 (0.81 to 0.99; P=0.031), respectively. If corroborated by other large-scale, prospective studies, our findings indicate that the natriuretic peptide precursor A gene plays a significant role in blood pressure regulation and development of hypertension.


Key Words: blood pressure • hypertension • natriuretic peptide precursor A • gene polymorphism • atrial natriuretic peptide